drugset
drugset / Trial / NCT02575404

GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients

NCT02575404 ↗

Phase 1 Completed 36 enrolled Providence Health & Services Galectin Therapeutics Inc. · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study is a dose escalation of GR-MD-02 with the standard therapeutic dose of pembrolizumab in patients with advanced melanoma, non-small cell lung cancer, and head and neck squamous cell cancer.

Timeline

Start
2016-05-16
Primary completion
2021-01-12
Completion
2022-10-10

Drugs

EvaluationDrugModalityDoseRoute
Subject belapectin Other / unclassified 2 mg/kg Intravenous
Subject belapectin Other / unclassified 4 mg/kg Intravenous
Subject belapectin Other / unclassified 8 mg/kg Intravenous
Background Pembrolizumab Monoclonal antibody 200 mg Intravenous

Indications

head and neck squamous cell carcinoma melanoma non-small cell lung carcinoma